Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 3000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrands disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 4000 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1000 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated or use in haemophilia a for prevention and control of haermorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von wllebrand's disease

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 250 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of harmorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 2000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1000 [iu];   - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1500 [iu];   - injection with diluent - 1500 iu - active: octocog alfa 1500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 2000 [iu];   - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.